Interview with Dr James Garner, CEO of Kazia Therapeutics
Regulatory March 24, 2023Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party
Non Regulatory March 20, 2023Vivesto initiates clinical development of Paccal Vet in veterinary oncology
Regulatory February 23, 2023Year-end report for the financial year January 1 – December 31, 2022
Vivesto published its Year-end Report for 2022 on February 23, 2023, at 07:30 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program